Analysts expect that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will report earnings of ($0.06) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Catalyst Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.08) and the highest estimate coming in at ($0.05). Catalyst Pharmaceuticals also posted earnings per share of ($0.06) in the same quarter last year. The firm is scheduled to report its next earnings results on Tuesday, August 8th.

On average, analysts expect that Catalyst Pharmaceuticals will report full year earnings of ($0.26) per share for the current year, with EPS estimates ranging from ($0.32) to ($0.22). For the next fiscal year, analysts expect that the firm will post earnings of ($0.23) per share, with EPS estimates ranging from ($0.33) to ($0.15). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.06).

Several analysts have commented on CPRX shares. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research note on Monday, May 22nd. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Catalyst Pharmaceuticals in a research note on Monday, March 20th. Finally, Roth Capital set a $3.00 price target on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, March 20th.

TRADEMARK VIOLATION NOTICE: “-$0.06 Earnings Per Share Expected for Catalyst Pharmaceuticals Inc (CPRX) This Quarter” was published by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.watchlistnews.com/0-06-earnings-per-share-expected-for-catalyst-pharmaceuticals-inc-cprx-this-quarter/1352628.html.

Catalyst Pharmaceuticals (CPRX) traded up 3.46% on Thursday, reaching $2.39. The company had a trading volume of 960,555 shares. The stock’s 50 day moving average price is $2.00 and its 200-day moving average price is $1.47. Catalyst Pharmaceuticals has a 12-month low of $0.63 and a 12-month high of $2.43. The stock’s market capitalization is $200.25 million.

A number of hedge funds have recently made changes to their positions in CPRX. Candriam Luxembourg S.C.A. bought a new stake in shares of Catalyst Pharmaceuticals during the first quarter valued at approximately $1,170,000. Berson & Corrado Investment Advisors LLC boosted its stake in shares of Catalyst Pharmaceuticals by 31.7% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 251,025 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 60,425 shares during the last quarter. Knott David M bought a new stake in shares of Catalyst Pharmaceuticals during the first quarter valued at approximately $554,000. Kingdon Capital Management L.L.C. bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $794,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Catalyst Pharmaceuticals during the first quarter valued at approximately $746,000. Institutional investors and hedge funds own 28.13% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Catalyst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.